Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337044 | 1.00 | ATM (0.34) | ATMMMP2ANPEPDPP7DPP8 | |
| SCHEMBL17374461 | 0.83 | MMP2 (0.36) | ATMMMP2ANPEPDPP7DPP8 | |
| SCHEMBL19032334 | 0.83 | MMP2 (0.36) | ATMMMP2ANPEPDPP7DPP8 | |
| SCHEMBL17374459 | 0.83 | MMP2 (0.36) | ATMMMP2ANPEPDPP7DPP8 | |
| SCHEMBL27948408 | 0.77 | NAAA (0.36) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL425737 | 0.77 | — | — | |
| SCHEMBL28439266 | 0.75 | — | — | |
| Water SCHEMBL8681204 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL11162708 | 0.75 | — | — | |
| SCHEMBL28566126 | 0.74 | ATM (0.32) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533924-B | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-112533924-A | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-107849039-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3313840-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10294229-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180186799-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294229-B2 | Heteroaryl substituted aminopyridine compounds | IRAK4, IRAK3, IRAK2 | ATM 1731/4885MMP2 3588/4885ANPEP 4546/4885 |
| US-20180186799-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | IRAK4, IRAK3, IRAK2 | ATM 1731/4885MMP2 3588/4885ANPEP 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.